C-4VXPBetalin Therapeutics
stem cells, tissue engineering, beta cells
replacementreplacingcell therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
All companiesC-4VXP
C-4VXPC-4VXPstem cells, tissue engineering, beta cells
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Betalin Therapeutics states that diabetes treatment can be transformed by replacing insulin therapy with its Engineered Micro Pancreas (EMP), an innovative, game-changing therapy intended to improve quality of life for millions of people with diabetes worldwide. The company presents EMP as a breakthrough and the future of diabetes treatment, supported by licensed university technology and promising early in vitro and preliminary in vivo results.
SourceBetalin Therapeutics presents the belief that Type 1 diabetes can be treated with an implantable tissue-engineered micro-pancreas containing living cells that sense glucose and produce insulin in a regulated way, thereby providing the function of a healthy endocrine pancreas and potentially freeing patients from frequent insulin injections and glucose monitoring through a minimally invasive transplantation procedure.
SourceBetalin Therapeutics presents the view that Type 1 diabetes can be treated with an implantable tissue-engineered micro-pancreas containing living cells that sense glucose and secrete insulin in a regulated way, reproducing the function of a healthy endocrine pancreas and potentially freeing patients from frequent insulin injections and glucose monitoring through a minimally invasive transplantation procedure.
Source